198 related articles for article (PubMed ID: 11570815)
41. Negative chronotropic response to adenosine receptor stimulation in rat right atria after run training.
Priviero F; De Nucci G; Antunes E; Zanesco A
Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):741-3. PubMed ID: 15554918
[TBL] [Abstract][Full Text] [Related]
42. Pharmacological analysis of calcium responses mediated by the human A3 adenosine receptor in monocyte-derived dendritic cells and recombinant cells.
Fossetta J; Jackson J; Deno G; Fan X; Du XK; Bober L; Soudé-Bermejo A; de Bouteiller O; Caux C; Lunn C; Lundell D; Palmer RK
Mol Pharmacol; 2003 Feb; 63(2):342-50. PubMed ID: 12527805
[TBL] [Abstract][Full Text] [Related]
43. Effects of synthetic A3 adenosine receptor agonists on cell proliferation and viability are receptor independent at micromolar concentrations.
Mlejnek P; Dolezel P; Frydrych I
J Physiol Biochem; 2013 Sep; 69(3):405-17. PubMed ID: 23184730
[TBL] [Abstract][Full Text] [Related]
44. A role for histamine in cytokine modulation by the adenosine A(3) receptor agonist, 2-Cl-IB-MECA.
Smith SR; Denhardt G; Terminelli C
Eur J Pharmacol; 2002 Dec; 457(1):57-69. PubMed ID: 12460644
[TBL] [Abstract][Full Text] [Related]
45. The infarct-sparing effect of IB-MECA against myocardial ischemia/reperfusion injury in mice is mediated by sequential activation of adenosine A3 and A 2A receptors.
Tian Y; Marshall M; French BA; Linden J; Yang Z
Basic Res Cardiol; 2015 Mar; 110(2):16. PubMed ID: 25711314
[TBL] [Abstract][Full Text] [Related]
46. p53-Independent induction of Fas and apoptosis in leukemic cells by an adenosine derivative, Cl-IB-MECA.
Kim SG; Ravi G; Hoffmann C; Jung YJ; Kim M; Chen A; Jacobson KA
Biochem Pharmacol; 2002 Mar; 63(5):871-80. PubMed ID: 11911839
[TBL] [Abstract][Full Text] [Related]
47. Activation of A(3) adenosine receptor induces calcium entry and chloride secretion in A(6) cells.
Reshkin SJ; Guerra L; Bagorda A; Debellis L; Cardone R; Li AH; Jacobson KA; Casavola V
J Membr Biol; 2000 Nov; 178(2):103-13. PubMed ID: 11083899
[TBL] [Abstract][Full Text] [Related]
48. Synthesis of 3'-fluoro analogue of Cl-IB-MECA as adenosine A3 receptor ligand.
Chun MW; Lim MH; Moon HR; Kim HO; Jacobson KA; Jeong LS
Nucleic Acids Res Suppl; 2003; (3):19-20. PubMed ID: 14510359
[TBL] [Abstract][Full Text] [Related]
49. Adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth.
Fishman P; Bar-Yehuda S; Vagman L
Cancer Res; 1998 Jul; 58(14):3181-7. PubMed ID: 9679987
[TBL] [Abstract][Full Text] [Related]
50. Resistance of muscle to tumor metastases: a role for a3 adenosine receptor agonists.
Bar-Yehuda S; Barer F; Volfsson L; Fishman P
Neoplasia; 2001; 3(2):125-31. PubMed ID: 11420748
[TBL] [Abstract][Full Text] [Related]
51. Adenosine acts as an inhibitor of lymphoma cell growth: a major role for the A3 adenosine receptor.
Fishman P; Bar-Yehuda S; Ohana G; Pathak S; Wasserman L; Barer F; Multani AS
Eur J Cancer; 2000 Jul; 36(11):1452-8. PubMed ID: 10899660
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101.
Ohana G; Bar-Yehuda S; Arich A; Madi L; Dreznick Z; Rath-Wolfson L; Silberman D; Slosman G; Fishman P
Br J Cancer; 2003 Oct; 89(8):1552-8. PubMed ID: 14562031
[TBL] [Abstract][Full Text] [Related]
53. Cl-IB-MECA inhibits human erythropoiesis.
Bhanu NV; Aerbajinai W; Gantt NM; Jackson EK; Goh SH; Terry Lee Y; Miller JL
Br J Haematol; 2007 May; 137(3):233-6. PubMed ID: 17408462
[TBL] [Abstract][Full Text] [Related]
54. Selective A3 adenosine receptor agonist protects against doxorubicin-induced cardiotoxicity.
Galal A; El-Bakly WM; Al Haleem EN; El-Demerdash E
Cancer Chemother Pharmacol; 2016 Feb; 77(2):309-22. PubMed ID: 26676227
[TBL] [Abstract][Full Text] [Related]
55. Adenosine acts through an A3 receptor to prevent the induction of murine anti-CD3-activated killer T cells.
Hoskin DW; Butler JJ; Drapeau D; Haeryfar SM; Blay J
Int J Cancer; 2002 May; 99(3):386-95. PubMed ID: 11992407
[TBL] [Abstract][Full Text] [Related]
56. Activation of the A3 adenosine receptor affects cell cycle progression and cell growth.
Brambilla R; Cattabeni F; Ceruti S; Barbieri D; Franceschi C; Kim YC; Jacobson KA; Klotz KN; Lohse MJ; Abbracchio MP
Naunyn Schmiedebergs Arch Pharmacol; 2000 Mar; 361(3):225-34. PubMed ID: 10731034
[TBL] [Abstract][Full Text] [Related]
57. A3 adenosine receptor agonist induce G1 cell cycle arrest via Cyclin D and cyclin-dependent kinase 4 pathways in OVCAR-3 and Caov-4 cell lines.
Joshaghani HR; Jafari SM; Aghaei M; Panjehpour M; Abedi H
J Cancer Res Ther; 2017; 13(1):107-112. PubMed ID: 28508842
[TBL] [Abstract][Full Text] [Related]
58. The combination of Cl-IB-MECA with paclitaxel: a new anti-metastatic therapeutic strategy for melanoma.
Soares AS; Costa VM; Diniz C; Fresco P
Cancer Chemother Pharmacol; 2014 Oct; 74(4):847-60. PubMed ID: 25119183
[TBL] [Abstract][Full Text] [Related]
59. A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition.
Madi L; Bar-Yehuda S; Barer F; Ardon E; Ochaion A; Fishman P
J Biol Chem; 2003 Oct; 278(43):42121-30. PubMed ID: 12865431
[TBL] [Abstract][Full Text] [Related]
60. A(3) adenosine receptor activation during reperfusion reduces infarct size through actions on bone marrow-derived cells.
Ge ZD; van der Hoeven D; Maas JE; Wan TC; Auchampach JA
J Mol Cell Cardiol; 2010 Aug; 49(2):280-6. PubMed ID: 20132822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
